Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer
- PMID: 21947124
- DOI: 10.1007/s00066-011-2246-2
Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer
Abstract
Background and purpose: To present the feasibility and results of accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) in the treatment of locally advanced head and neck cancer.
Patients and methods: A total of 65 patients were treated between June 2006 and August 2009. The distribution of clinical stages was as follows: II 11%, III 23%, IV 61%, and not defined 5%.
Results: The median follow-up was 30.5 months. The treatment plan was completed in 94% of patients. Patients were treated using the conformal or intensity-modulated radiotherapy (IMRT) technique. The median overall treatment time was 37 days (13-45 days). The mean radiotherapy dose was 68.4 Gy (16-74 Gy). Overall survival was 69% after 2 years. Disease-free survival was 62% after 2 years. Acute toxicity ≥ grade 3(RTOG scale) included mucositis (grade 3: 42.6%), pharynx (grade 3: 42.3%), skin (grade 3: 9.5%), larynx (grade 3: 4%), while late toxicity affected skin (grade 3: 6.25%) and salivary glands (grade 3: 3.7%).
Conclusion: Accelerated radiotherapy with concomitant boost technique is feasible in patients with locally advanced head and neck cancer, has an acceptable toxicity profile, and yields promising treatment results.
Similar articles
-
Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.Strahlenther Onkol. 2012 Aug;188(8):666-70. doi: 10.1007/s00066-012-0128-x. Epub 2012 Jun 1. Strahlenther Onkol. 2012. PMID: 22648405 Clinical Trial.
-
Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy.Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):21-32. doi: 10.1016/s0360-3016(99)00101-7. Int J Radiat Oncol Biol Phys. 1999. PMID: 10477002
-
Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.Strahlenther Onkol. 2013 Mar;189(3):223-9. doi: 10.1007/s00066-012-0289-7. Epub 2013 Jan 16. Strahlenther Onkol. 2013. PMID: 23319256
-
[SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].Otolaryngol Pol. 2011 Sep;65(5 Suppl):117-25. doi: 10.1016/S0030-6657(11)70719-3. Otolaryngol Pol. 2011. PMID: 22000261 Polish.
-
Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):374-87. doi: 10.1016/j.ijrobp.2004.03.010. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380569 Clinical Trial.
Cited by
-
Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects.Cancers (Basel). 2023 Apr 30;15(9):2580. doi: 10.3390/cancers15092580. Cancers (Basel). 2023. PMID: 37174046 Free PMC article.
-
Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.Strahlenther Onkol. 2012 Aug;188(8):666-70. doi: 10.1007/s00066-012-0128-x. Epub 2012 Jun 1. Strahlenther Onkol. 2012. PMID: 22648405 Clinical Trial.
-
[2014: activation of OPS 8-980 "Complex intensive care treatment" by DIMDI].Med Klin Intensivmed Notfmed. 2014 Feb;109(1):61. doi: 10.1007/s00063-013-0313-4. Epub 2013 Dec 20. Med Klin Intensivmed Notfmed. 2014. PMID: 24352621 German. No abstract available.
-
Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer.In Vivo. 2021 Jan-Feb;35(1):411-415. doi: 10.21873/invivo.12272. In Vivo. 2021. PMID: 33402490 Free PMC article.
-
Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy. Outcome in patients with locally advanced head and neck cancer.Strahlenther Onkol. 2013 Aug;189(8):618-24. doi: 10.1007/s00066-013-0397-z. Epub 2013 Jul 4. Strahlenther Onkol. 2013. PMID: 23821138 Clinical Trial.
References
MeSH terms
LinkOut - more resources
Full Text Sources